Our work focuses on translating imaging analysis methods to better understand processes such as brain maturation and ageing, and with a particular emphasis on neurodegenerative disorders (Alzheimer's, Parkinson's, Huntington's, ALS).
Our research stems from the strong conviction that multidisciplinary research benefits from researchers truly working at the interface between the different disciplines involved. This holds particularly true when imaging is used to further our understanding of normal and abnormal brain processes.
For instance, we developed in FSL, the brain imaging analysis software developed in the FMRIB Analysis group, a specific tool that makes it possible to assess cross-sectionally or longitudinally the localised grey matter volume differences or changes between populations. This was used to demonstrate anatomically-related grey and white matter abnormalities in early-onset schizophrenia, and the interplay of the disease with brain maturation (Brain 2007, Brain 2009), but has also been extensively used in >200 published studies. We developed a novel method to integrate structural and functional connectivity information related to a specific disease process and used it to reveal a possible failure of GABA interneurons in ALS, suggesting new therapeutic target for this devastating disease (Brain 2011). Another "bench to bedside" example is that, by using our FSL tool and the latest methods in Bayesian causal modelling, we have established the beneficial effect of vitamin B to drastically reduce grey matter atrophy in MCI subjects (PNAS 2013).
This multidisciplinary approach will be applied to our most recent project, which will focus on the basal ganglia circuitry in health and movement disorders, structures that are wired together and process information in a highly computational manner. Failure in this very complex system can lead, for instance, to movement disorders such as Parkinson's or Huntington's. For more details, please see my personal webpage.
- Adam Aron (UCSD Psychology Department, San Diego CA)
- A. David Smith (MRC Anatomical Neuropharmacology Unit, Oxford)
- Paul Bolam (MRC Anatomical Neuropharmacology Unit, Oxford)
- Suzanne Haber (University of Rochester Medical Centre, Rochester NY)
- Lars T. Westlye (Department of Psychology, University of Oslo)
- Anders M. Fjell (Department of Psychology, University of Oslo)